Sign In
Buy TBPH
$15.92
+0.340 (+2.18%)
At Close: Jun 03, 2026
Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio
06:06am, Wednesday, 15'th Sep 2021
DUBLIN and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced strategic actions to focus on
DUBLIN and SOUTH SAN FRANCISCO, Calif., Sept, 15, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), a diversified biopharmaceutical company prim
Steven Cohen Boosts Health Care Exposure With Theravance Biopharma Stake
05:55pm, Wednesday, 08'th Sep 2021
Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed a 7% stake in Theravance Biopharma Inc. ( TBPH , Financial) earlier this week.
7 Busted Biotech Stocks Due for a Rebound
12:25pm, Wednesday, 08'th Sep 2021
Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on
Here's Why Theravance Biopharma Stock Is Tanking Today
03:02pm, Tuesday, 24'th Aug 2021
The company's second clinical-trial flop in as many months isn't sitting well with investors.
Theravance (TBPH) Suffers 2nd Study Failure in Two Months
10:41am, Tuesday, 24'th Aug 2021
Theravance's (TBPH) mid-stage candidate, izencitinib, fails in a study evaluating it in patients with ulcerative colitis.
Theravance Biopharma Shares Fall Over 25% Pre-Market: Why It Happened
07:50am, Tuesday, 24'th Aug 2021
The shares of Theravance Biopharma Inc (NASDAQ: TBPH) fell by over 25% pre-market. This is why it happened.
Theravance Stock Plunges As JAK Inhibitor Flops Ulcerative Colitis Study
06:16am, Tuesday, 24'th Aug 2021
Theravance Biopharma Inc's (NASDAQ: TBPH) Izencitinib, a "gut-selective" JAK inhibitor developed for ulcerative colitis and Crohn's disease, failed a key Phase 2 trial. Johnson & Johnson's (NYSE: J
Theravance Bio stock falls more than 20% after drug trial disappoints
04:51pm, Monday, 23'rd Aug 2021
Shares of Theravance Biopharma Inc. TBPH, +0.85% fell more than 20% in the extended session Monday after the biopharmaceutical company said that a dose-finding study of one of its drugs, izencitinib,
DUBLIN and SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), a diversified biopharmaceutical company prim
Theravance's (TBPH) Q2 Earnings Beat, Pipeline On Track
11:28am, Wednesday, 04'th Aug 2021
Theravance's (TBPH) loss narrows in the second quarter of 2021 while revenues decline year over year. Stock up.
Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q2 2021 Results - Earnings Call Transcript
11:09pm, Tuesday, 03'rd Aug 2021
Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q2 2021 Results - Earnings Call Transcript
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
07:04pm, Tuesday, 03'rd Aug 2021
Theravance Bio (TBPH) delivered earnings and revenue surprises of 16.67% and -14.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Theravance Biopharma Q2 Earnings
04:50pm, Tuesday, 03'rd Aug 2021
Shares of Theravance Biopharma (NASDAQ:TBPH) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 20.00% year over year to ($0.80), which
Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
04:00pm, Tuesday, 03'rd Aug 2021
DUBLIN, Aug. 3, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter of 2021. "We made stro
